Response-adaptive randomization with imperfect intermediate endpoints
Given the objective of evaluating several new therapeutic regimens in a timely manner, response-adaptive randomization is tempting. However, it requires at least reliance on highly accurate intermediate endpoints, which are still no guarantee of response-adaptive randomization's trustworthiness.
Authors
- Yousra Kherabi (ORCID: https://orcid.org/0000-0002-6201-426X)
- Lori E. Dodd (ORCID: https://orcid.org/0000-0002-3433-5429)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Université Sorbonne Paris Nord (FR)
- National Institute of Allergy and Infectious Diseases (US)
- Hôpital Bichat-Claude-Bernard (FR)
Publication Details
- Journal
- Clinical Trials
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1177/17407745261415792
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00